Table 2.

Interventions included in the literature review^*

Intervention	Name/type
NSAIDs	Any
DMARDs	Leflunomide, methotrexate, sulfasalazine, triple non–biologic DMARD (methotrexate, sulfasalazine, hydroxychloroquine)†
Biologics TNFi	Adalimumab, etanercept, infliximab, golimumab†
Non–TNFi	Abatacept (CTLA-4Ig), tocilizumab (anti– interleukin-6 receptor), rituximab (anti- CD20)‡
Glucocorticoids
Oral	Any Triamcinolone acetonide, triamcinolone
Intraarticular	hexacetonide, methylprednisolone acetate
Other interventions	Physical therapy Occupational therapy

^*NSAIDs = nonsteroidal antiinflammatory drugs; DMARDs = disease-modifying antirheumatic drugs; TNFi = tumor necrosis factor inhibitor.

^†Certolizumab was not included in the recommendations because no pediatric data were yet available.

^‡Evaluated for polyarthritis only.